> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# RSVpreF Vaccine Meets Endpoints
- URL: https://www.fdaweb.com/rsvpref-vaccine-meets-endpoints/
- Published: 2023-04-06T12:00:00.000Z
- Updated: 2026-09-14T18:24:20.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5154156

Researchers from the University of Rochester and around the world who are members of the RENOIR Clinical Trial Group say a Phase 3 trial of Pfizer’s investigational bivalent RSV (respiratory syncytial virus) prefusion F protein-based (RSVpreF) vaccine prevented RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in older adults without evident safety concerns. The Pfizer-supported research was [reported](ttps://www.nejm.org/doi/full/10.1056/NEJMoa2213836?query=featured%5Fhome) in the *New England Journal of Medicine*.

The study says the two primary endpoints were vaccine efficacy against seasonal RSV-associated lower respiratory tract illness with at least two or at least three signs or symptoms. The secondary endpoint was vaccine efficacy against RSV-associated respiratory illness.